Efficacy of autologous platelet‐rich plasma combined with a non‐cross‐linked hyaluronic acid compound in the treatment of female androgenetic alopecia: A retrospective, case‐series study

    June 2023 in “Journal of Cosmetic Dermatology
    TLDR The treatment combining platelet-rich plasma and a non-cross-linked hyaluronic acid compound significantly improved hair density and reduced bald areas in women with androgenetic alopecia, and it's safe with only mild side effects.
    The retrospective, case-series study involved 9 female patients with androgenetic alopecia (FAGA) and evaluated the efficacy of a treatment combining autologous platelet-rich plasma (PRP) and a non-cross-linked hyaluronic acid (HA) compound. The treatment led to a significant improvement in hair density and reduction in areas of alopecia, with a 54.51% increase in hair count at 1 month and a 77.25% increase at 3 months. The treatment's clinical efficacy could last beyond 3 months, and patients reported high satisfaction levels. Mild side effects occurred but resolved within 72 hours, and no serious adverse events occurred, indicating the treatment is safe and well-tolerated. The study concluded that the combination of PRP and non-cross-linked HA compound is effective and safe in treating FAGA, but further randomized controlled trials with larger sample sizes are needed to confirm these findings.
    View this study on onlinelibrary.wiley.com →

    Cited in this study